Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2091-2100

  You, Nan ^a   Liu, Weihui ^a,b   Wang, Tao ^a   Ji, Ru ^a   Wang, Xing ^a   Gong, Zhenbing ^a   Dou, Kefeng ^a   Tao, Kaishan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Growth; Hepatocellular carcinoma; Paclitaxel; Swainsonine

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; SWAINSONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRAIN HL 7702; CELL STRAIN HUH7; CELL STRAIN MHCC97 H; CELL STRAIN SMCC7721; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTRAGALUS MEMBRANACEUS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SYNERGISM; FAS LIGAND PROTEIN; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; PACLITAXEL; SWAINSONINE;

EID: 84868106519     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2035     Document Type: Conference Paper

References (40)

1. Lin H, Van Den Esschert J, Liu C and Van Gulik TM: Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol 26:28-35, 2011.
2. Villanueva A and Llovet JM: Targeted therapies for hepatocellular carcinoma. Gastroenterology 140:1410-1426, 2011.
3. Yang JD and Roberts LR: Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7:448-458, 2010.
4. Sanoff HK, Bernard S, Goldberg RM, et al: Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res 4:8-83, 2011.
5. Okano J, Nagahara T, Matsumoto K and Murawaki Y: The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal-regulated kinase and apoptosis. Oncol Rep 17:1195-1200, 2007.
6. Caicedo-Granados EE, Wuertz BR, Marker PH, Lee GS and Ondrey FG: The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition. Arch Otolaryngol Head Neck Surg 137:799-805, 2011.
7. Sreekanth CN, Bava SV, Sreekumar E and Anto RJ: Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 30:3139-3152, 2011.
8. Kelly MG, Alvero AB, Chen R, et al: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859-3868, 2006.
9. Baines AT, Xu D and der CJ: Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 3:1787-1808, 2011.
10. Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H and Gabra H: DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 13:1069-1080, 2011.
11. Luedde T and Schwabe RF: NF-κB in the liver - linking injury, fbrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8:108-118, 2011.
12. Luqman S and Pezzuto JM: NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res 24:949-963, 2010.
13. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F and Fernandez-Luna JL: The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2:646-653, 2011.
14. Goss PE, Baptiste J, Fernandes B, Baker M and Dennis JW: A phase I study of swainsonine in patients with advanced malignancies. Cancer Res 54:1450-1457, 1994. (Pubitemid 24106405)
15. Santos FM, Latorre AO, Hueza IM, Sanches DS, Lippi LL, Gardner DR and Spinosa HS: Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo. Phytomedicine 18:1096-1101, 2011.
16. Sun J Y, Yang H, Miao S, et al: Suppressive effects of swainsonine on C6 glioma cell in vitro and in vivo. Phytomedicine 16:1070-1074, 2009.
17. You N, Liu W, Zhong X, et al: Tg737 inhibition results in malignant transformation in fetal liver stem/progenitor cells by promoting cell-cycle progression and differentiation arrest. Mol Carcinog 51:659-673, 2012.
18. Alves RC, Alves D, Guz B, et al: Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 10:21-27, 2011.
19. Karikas GA: Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J BUON 15:627-638, 2010.
20. Tulsiani DR and Touster O: Swainsonine, a potent mannosidase inhibitor, elevates rat liver and brain lysosomal alpha-D-mannosidase, decreases Golgi alpha-D-mannosidase II, and increases the plasma levels of several acid hydrolases. Arch Biochem Biophys 224:594-600, 1983. (Pubitemid 13032703)
21. Van Den Elsen JM, Kuntz DA and Rose DR: Structure of Golgi alpha-mannosidase II: a target for inhibition of growth and metastasis of cancer cells. EMBO J 20:3008-3017, 2001. (Pubitemid 32611988)
22. Shaheen PE, Stadler W, Elson P, Knox J, Winquist E and Bukowski RM: Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs 23:577-581, 2005. (Pubitemid 43162478)
23. Yanagida K, Natsuka S and Hase S: Structural diversity of cytosolic free oligosaccharides in the human hepatoma cell line, HepG2. Glycobiology 16:294-304, 2006.
24. Yeo TK, Yeo KT, Parent JB and Olden K: Swainsonine treatment accelerates intracellular transport and secretion of glycoproteins in human hepatoma cells. J Biol Chem 260:2565-2569, 1985.
25. Williams GH and Stoeber K: The cell cycle and cancer. J Pathol 226:352-364, 2012.
26. Fang J, Yu Z, Lian M, Ma H, Tai J, Zhang L and Han D: Knockdown of zinc finger protein, X-linked (ZFX) inhibits cell proliferation and induces apoptosis in human laryngeal squamous cell carcinoma. Mol Cell Biochem 360:301-307, 2012.
27. Hu W, Shen T and Wang MH: Cell cycle arrest and apoptosis induced by methyl 3, 5-dicaffeoyl quinate in human colon cancer cells: Involvement of the PI3K/Akt and MAP kinase pathways. Chem Biol Interact 194:48-57, 2011.
28. Palumbo C, Bei R, Procopio A and Modesti A: Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem 15:855-867, 2008. (Pubitemid 351736408)
29. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253:453-469, 2011.
30. Johansson M and Persson JL: Cancer therapy: targeting cell cycle regulators. Anticancer Agents Med Chem 8:723-731, 2008.
31. Chang HR, Lian JD, Lo CW, Chang YC, Yang MY and Wang CJ: Induction of urothelial proliferation in rats by aristolochic acid through cell cycle progression via activation of cyclin D1/cdk4 and cyclin E/cdk2. Food Chem Toxicol 44:28-35, 2006.
32. Chen K, Perez-Stable C, D'Ippolito G, Schiller PC, Roos BA and Howard GA: Human bone marrow-derived stem cell proliferation is inhibited by hepatocyte growth factor via increasing the cell cycle inhibitors p53, p21 and p27. Bone 49:1194-1204, 2011.
33. Sayers TJ: Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60:1173-1180, 2011.
34. Chowdhury I, Tharakan B and Bhat GK: Current concepts in apoptosis: the physiological suicide program revisited. Cell Mol Biol Lett 11:506-525, 2006. (Pubitemid 46708878)
35. He G and Karin M: NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 21:159-168, 2011.
36. Deeb D, Gao X, Dulchavsky SA and Gautam SC: CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells. J Exp Ther Oncol 7:31-39, 2008. (Pubitemid 351521215)
37. Ma Y, Wang J, Liu L, et al: Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Lett 301:75-84, 2011.
38. Matsubara J, Shimada Y, Kato K, et al: Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer. Oncology 81:291-297, 2011.
39. Fujiwara Y, Furukawa K, Shimada Y, et al: Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer. Pancreas 40:600-607, 2011.
40. Pasqualetti G, Ricciardi S, Mey V, Del Tacca M and Danesi R: Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung Cancer 74:197-205, 2011.